drugset / Trial / NCT02267460

An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease

NCT02267460

Phase 3 Completed 30 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupOpen-labelTreatment

Summary

Enrollment will include approximately 30 AA4500 naïve subjects. Subjects will be divided by degree of penile curvature and then randomized in a 1:1 ratio to one of the following treatment groups: * AA4500 with investigator modeling * AA4500 without investigator modeling Each subject will receive 2 injections of AA4500, separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles. Approximately 14 days after the second injection of AA4500, each subject will visit the study site and the investigator will assess the subject and instruct the subject on appropriate use of the ErecAid® Esteem® Manual Vacuum Therapy System.

Timeline

Start
2014-10
Primary completion
2015-10
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Collagenase Clostridium Histolyticum Protein / enzyme biologic 0.58 mg Other

Indications